Join
Live feed
·
PRReleasevia Quantisnow
Gain Therapeutics Inc. logo

Gain Therapeutics Presents Positive Interim Data from Phase 1b Clinical Study of GT-02287 at 3rd International GBA1 Meeting 2026

ByQuantisnow·Wall Street's wire, on your screen.
GANX· Gain Therapeutics Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track GANX (Gain Therapeutics Inc.) and more on Quantisnow.